Mistral Ventures Inc (PINK:MILV) Pops Up In Late Morning Session

Shares of Mistral Ventures Inc  (PINK:MILV) turned higher sharply after initial fall as the company released a press release stating that it has reached an agreement with its own subsidiary Nature’s Bioceuticals, which has been working on inventing spectacular cold and flu medicine over the many years.

Although, sales of cold and flu formulas have shown lackluster growth period in the past couple of years, the company is very optimistic about its innovation and projects to provide potentially $100 or 3% of the US market in revenue over the next three years.

In the past, OTC products have not shown impressive results due to their bad press, a number of recalls and FDA recommendations. In on March 2, 2011 the FDA decided to remove over 500 prescription cold, cough, and allergy products from the market, stating potential safety concerns.

The company stated that its innovation contains over twenty different herbs that are all ‘active ingredients,’ which would be sufficient to provide relief from the cold and flu symptoms, but more importantly, it boosts the body’s immune response to combat the cause of the virus.

Shares of MILV are trading higher by 37.78% to $0.062 after opening lower by about 10%. More than 133.54 million shares have already exchanged hands within first three-hour of trading session, compared to its 30-day average volume of 290K shares.


The assembled information distributed by headlineotc.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Headlineotc.com does expect that investors will buy and sell securities based on information assembled and presented herein. Headlineotc.com will not be responsible in any way for or accept any liability for any losses arising from an investor’s reliance on or use of information obtained from our website or emails. PLEASE always do your own due diligence, and consult your financial advisor.

Our Research Report on MILV is now available. Don´t Trade MILV until you Read our FREE FULL REPORT. Click Here